At the 2026 World Economic Forum Annual Meeting of the New Champions in Dalian, the CEO of SBP GROUP (HKG: 01177) shared insights on the company's evolution and the broader trajectory of China's pharmaceutical industry.

He stated that as one of China's leading pharmaceutical firms, the company now boasts a comprehensive new drug development pipeline, with annual R&D investment exceeding 6 billion yuan.

Strategic Evolution and Core Strengths

He highlighted a significant strategic shift for the company, moving from a previously narrow product focus to a broad coverage of fundamental healthcare needs. The company now concentrates on six major therapeutic areas, including liver disease, surgery, and oncology. After years of development, it has established several blockbuster core products. He expressed strong confidence in the vast growth potential within both the oncology and liver disease sectors, noting that the promising potential of multiple pipelines is a core competitive advantage.

Expanding Global Footprint

The CEO acknowledged that the company's operations were once heavily concentrated on the domestic market but have, in recent years, embarked on a comprehensive globalization strategy. He emphasized that the company will continue to expand global partnerships, which he believes will not only bolster its domestic market position but also facilitate its entry and growth in international markets.

Outlook for Chinese Pharmaceutical Firms

Looking ahead, he predicted that an increasing number of Chinese enterprises will develop the capability to build global pipelines, utilizing various forms of international cooperation to establish worldwide sales channels. He expressed strong optimism about Chinese pharmaceutical companies, foreseeing their gradual leadership in international multi-center clinical trials. He envisions them synchronously developing global markets and building bridges for pharmaceutical R&D that connect China with the rest of the world.